Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound

Abstract The anticancer activity of bortezomib (BTZ) has been increasingly studied in a number of indications and promising results for the use of this treatment have been shown in neuroblastoma. As BTZ treatment is usually administered in cycles, the development of resistance and side effects in pa...

Full description

Bibliographic Details
Main Authors: Karolina Łuczkowska, Katarzyna Ewa Sokolowska, Olga Taryma-Lesniak, Krzysztof Pastuszak, Anna Supernat, Jonas Bybjerg-Grauholm, Lise Lotte Hansen, Edyta Paczkowska, Tomasz K. Wojdacz, Bogusław Machaliński
Format: Article
Language:English
Published: Nature Portfolio 2021-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-89128-0